Scalable Models For High-Performance Pharma R&D
Executive Summary
The superior R&D and growth performance of mid-sized companies like Celgene, Gilead, or Biogen can be attributed to a number of factors such as the size of the R&D budget, portfolio focus, a good mix of internal and external innovation sourcing, but most importantly a strong culture, leadership, and the ability to attract the right people. Part 3 of Catenion’s review of pharma R&D productivity.
You may also be interested in...
Global Biopharma R&D Productivity And Growth Ranking
An analysis of the R&D productivity of the world’s 30 largest public pharmaceutical companies reveals an overall drop in R&D productivity, but this should not hide the fact that some companies are still performing extremely well.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.